SAN DIEGO, April 15, 2016 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, today
announced leadership changes that will modify and expand the
responsibilities of key management members and support the
Company's ongoing growth strategies.
Robert H. Pierce, MD, Chief Scientific Officer, will
serve as Chief Scientific Strategist and Chairman of the Scientific
Advisory Board effective June 18,
2016. In this newly created position, Dr. Pierce will
continue to guide the scientific strategy of OncoSec's
immuno-oncology platform and identify strategic opportunities with
greatest need and best suited for the Company's technology. He will
also have the responsibility for reviewing clinical safety and
efficacy data to provide medical and strategic guidance to advance
the Company's product pipeline. At that time, Dr. Pierce will
transition from Chief Scientific Officer to consultant.
Dr. Pierce stated, "This transition will allow me to provide
strategic oversight on a very robust and versatile platform that I
helped to build, while allowing me to explore broader applications
and additional underpinnings of immuno-oncology in other
professional contexts. I am enthusiastic about the platform we have
created and the progress we have made in advancing our clinical
pipeline, and I believe the data we generate will continue to
demonstrate our leadership in this field."
Jean Campbell, PhD,
Executive Director of Research and Development, has been promoted
to Vice President of Research and Development, effective today. In
this position, Dr. Campbell will be responsible for building and
managing OncoSec's internal capabilities for proprietary drug
discovery and pre-clinical development to differentiate the
Company's immuno-oncology pipeline. She will also lead the
Discovery Research team in investigating new DNA constructs and
targets, and continue to hone OncoSec's pre-clinical programs and
novel electroporation device pipeline. Prior to joining
OncoSec in April 2014, Dr. Campbell
held several leadership positions at the School of Medicine at the
University of Washington, Seattle.
She possesses considerable expertise in cancer biology and
signal transduction to investigate mechanisms of immune tolerance
in cancer.
Punit Dhillon, President and CEO,
said, "Rob's career-long research into mechanisms of immune
tolerance and his expertise and passion in the field of
immuno-oncology and intratumoral immunotherapy are unparalleled.
Having built a solid proprietary platform for rapid discovery to
lead candidate selection with versatile clinical devices, Rob will
now focus his attention on advancing and applying applications of
OncoSec's technology, broadly in the field of intratumoral
immunotherapy. At the same time, Jean will focus her leadership in
driving our research and pre-clinical pipeline for multiple
clinical indications."
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse™,
for the treatment of cancer. ImmunoPulse™ is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various skin
cancers as well as the potential to initiate a systemic immune
response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently
in clinical development for several indications, including
metastatic melanoma, squamous cell carcinoma of the head and neck,
and triple-negative breast cancer. In addition to ImmunoPulse™
IL-12, the Company is also identifying and developing new
immune-targeting agents for use with the ImmunoPulse™ platform. For
more information, please visit www.oncosec.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as "expect," "may," "will," "goal,"
"intention," and similar references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data,
safety and technical issues; our ability to raise additional
funding necessary to fund continued operations; and the other
factors discussed in OncoSec's filings with the Securities and
Exchange Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
Contact
Mary
Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-announces-new-senior-leadership-responsibilities-300252369.html
SOURCE OncoSec Medical Incorporated